Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf J?rgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsg?rd Schambye in 2011 and is headquartered in Boston, MA.
No Data
No Data